Financial Results for Full Year 2007: NicOx Significantly Advances Clinica...( SOPHIA ANTIPOLIS France March 3 /...),Health

SOPHIA ANTIPOLIS, France, March 3 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced its financial results for 2007 and provided an overview of its activities during the year. NicOx also announced today the initiation of two large Ambulatory Blood Pressure Monitoring (ABPM) studies for naproxcinod (see separate press release).

Key highlights 2007:

-- Initiation of the two remaining pivotal phase 3 trials for naproxcinod

(the 302 and 303 studies) and completion of enrollment in the 302 study

-- Presentation of the naproxcinod phase 3 results at the American College

of Rheumatology (the 301 study) and data from an Ambulatory Blood

Pressure Monitoring trial at the American Heart Association (the 104

study)

-- Initiation of a phase 2 proof-of-concept study designed to compare the

safety and efficacy of PF-03187207 to Pfizer Inc's Xalatan

-- Start of clinical development for the first nitric oxide-donating

antihypertensive by Merck & Co., Inc.

-- Initiation of a phase 2 proof-of-concept study for TPI 1020 in Chronic

Obstructive Pulmonary Disease (COPD), following promising top-line

results in a phase 2a study in asthmatic smokers

-- Establishment of NicOx' United States (U.S.) headquarters in Warren,

New Jersey, as a base for Commercial Affairs and Clinical Operations in

North America

-- Strengthening of the Company's executive management team, through the

appointment of Pascal Pfister, MD as Chief Scientific Officer (CSO),

and Sanjiv Sharma as Vice President Commercial Affairs

"We envision that 2008 will be a transformational year for NicOx. We expect to complete the pivotal phase 3 program for naproxcinod, including a pooled analysis of the Office Blood Pressure Measurements, ahead of a projected New Drug Application filing in mid-2009," said Michele Garufi, Chair
'/>"/>